Today’s oxidative stress markers;Współczesne markery stresu oksydacyjnego

Medycyna Pracy

Volumn 66, Issue 3, 2015, Pages 393-405

  Czerska, Marta ^a   Mikołajewska, Karolina ^a   Zieliński, Marek ^a   Gromadzińska, Jolanta ^a   Wąsowicz, Wojciech ^a  

^a NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

Author keywords

Allantoin; Isoprostanes; Metabolites of isoprostanes; Oxidative stress; Oxidative stress markers

Indexed keywords

BIOLOGICAL MARKER; FREE RADICAL; REACTIVE OXYGEN METABOLITE;

HUMAN; LIPID PEROXIDATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; POLAND;

BIOMARKERS; FREE RADICALS; HUMANS; LIPID PEROXIDATION; OXIDATION-REDUCTION; OXIDATIVE STRESS; POLAND; REACTIVE OXYGEN SPECIES;

EID: 84942777559     PISSN: 04655893     EISSN: None     Source Type: Journal    
DOI: 10.13075/mp.5893.00137     Document Type: Article

References (59)

1. Prakash R, Singapalli T, Gokulnath. Review of oxidative stress in relevance to uremia. Clin Queries Nephrol. 2012; 1:215-21, http://dx.doi.org/10.1016/j.cqn.2012.06.002.
2. Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC. Oxidative stress, antioxidant therapies and chronic kidney disease. Nephrology. 2012;17:311-21, http://dx.doi.org/10.1111/j.1440-1797.2012.01572.x.
3. Yoshikawa T, Naito Y. What is oxidative stress? Jpn Med Assoc J. 2002;45(7):271-6.
4. Nikam S, Nikam P, Ahaley S, Sontakke A. Oxidative stress in Parkinson's disease. Indian J Clin Biochem. 2009;24: 98-101, http://dx.doi.org/10.1007/s12291-009-0017-y.
5. Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson's disease: A mechanism of pathogenic and therapeutic signifi-cance. Ann N Y Acad Sci. 2008;1147:93-104, http://dx.doi.org/10.1196/annals.1427.023.
6. Handelman GJ. Evaluation of oxidant stress in dialysis patients. Blood Purif. 2000;18:343-9, http://dx.doi. org/10.1159/000014460.
7. Sies H. Oxidants and antioxidants. Exp Physiol. 1997;82: 291-5, http://dx.doi.org/10.1113/expphysiol.1997.sp004024.
8. Locatelli F, Canaud B, Eckardt K-U, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol Dial Transplant. 2003;18:1272-80, http://dx.doi.org/10.1093/ ndt/gfg074.
9. Kand'ar R, Žakova P, Mužakova V. Monitoring of antioxidant properties of uric acid in humans for a consideration measuring of levels of allantoin in plasma by liquid chromatography. Clin Chim Acta. 2006;365:249-56, http://dx.doi.org/10.1016/j.cca.2005.09.002.
10. Berthemy A, Newton J, Wu D, Buhrman D. Quantitative determination of an extremely polar compound allantoin in human urine by LC-MS/MS based on the separation on a polymeric amino column. J Pharm Biomed Anal. 1999;19:429-34, http://dx.doi.org/10.1016/S0731-7085(98)00200-3.
11. Kim KM, Henderson GN, Frye RF, Galloway CD, Brown NJ, Segal MS, et al. Simultaneous determination of uric acid metabolites allantoin, 6-aminouracil, and triuret in human urine using liquid chromatography-mass spectrometry. J Chromatogr B. 2009;877:65-70, http:// dx.doi.org/10.1016/j.jchromb.2008.11.029.
12. Tolun AA, Zhang H, Il'yasova D, Sztaray J, Young SP, Millington DS. Allantoin in human urine quantified by UPLC-MS/MS. Anal Biochem. 2010;402(2):191-3, http:// dx.doi.org/10.1016/j.ab.2010.03.033.
13. Il'yasova D, Spasojevic I, Wang F, Tolun A, Base K, Young S, et al. Urinary biomarkers of oxidative status in a clinical model of oxidative assault. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1506-10, http://dx.doi. org/10.1158/1055-9965.EPI-10-0211.
14. Tolun AA, Scarbrough PM, Zhang H, McKilllop JA, Wang F, Kishnani PS, et al. Systemic oxidative stress, as measured by urinary allantoin and F2-isoprostanes, is not increased in Down syndrome. Ann Epidemiol. 2012;22: 892-4, http://dx.doi.org/10.1016/j.annepidem.2012.09.005.
15. Wu X, Lee Ch, Muzny D, Caskey T. Urate oxidase: Primary structure and evolutionary implications. Proc Natl Acad Sci U S A. 1989;86:9412-6, http://dx.doi.org/10.1073/ pnas.86.23.9412.
16. Grootveld M, Halliwell B. Measurement of allantoin and uric acid in human body fluids. A potential index of freeradical reactions in vivo? Biochem J. 1987;243:803-8.
17. Ames BN, Cathacart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant-and radical-cause aging and cancer: A hypothesis. Proc Natl Acad Sci U S A. 1981;78(11):6858-62, http:// dx.doi.org/10.1073/pnas.78.11.6858.
18. Moison RMW, de Beaufort AJ, Haasnoot AA, Dubbleman TM, van Zoern-Grobben D, Berger HM. Uric acid and ascorbic acid redox ratios in plasma and tracheal aspirate of preterm babies with acute and chronic lung disease. Free Radic Biol Med. 1997;23(2):226-34, http://dx.doi. org/10.1016/S0891-5849(97)00033-6.
19. Benzie IF, Chung W, Tomlinson B. Simultaneous measurement of allantoin and urate in plasma: Analytical evaluation and potential clinical application in oxidant: Antioxidant balance studies. Clin Chem. 1999;45(6):901-4.
20. Seet RC, Lee Ch-YJ, Loke WM, Huang SH, Huang H, Looi WF, et al. Biomarkers of oxidative damage in cigarette smokers: Which biomarkers might reflect acute versus chronic oxidative stress? Free Radic Biol Med. 2011;50:1787-93, http://dx.doi.org/10.1016/j.freeradbiomed. 2011.03.019.
21. Chung W-Y, Benzie IF. Plasma allantoin measurement by isocratic liquid chromatography with tandem mass spectrometry: Method evaluation and application in oxidative stress biomonitoring. Clin Chim Acta. 2013;424: 237-44, http://dx.doi.org/10.1016/j.cca.2013.06.015.
22. Il'yasova D, Kennedy K, Spasojevic I, Wang F, Tolun AA, Base K, et al. Individual responses to chemotherapy-induced oxidative stress. Breast Cancer Res Treat. 2011; 125(2):583-9, http://dx.doi.org/10.1007/s10549-010-1158-7.
23. Gus'kov EP, Prokof'ev VN, Kletskii ME, Kornienko IV, Gapurenko OA, Olekhnovich LP, et al. Allantoin as a Vitamin. Dokl Biochem Biophys. 2004;398:320-4, http://dx.doi.org/10.1023/B:DOBI.0000046649.11374.8d.
24. Yardim-Akaydim S, Sepici A, Ozkan Y, Torun M, Şimşek B, Sepici V. Oxidation of uric acid in rheumatoid arthritis: Is allantoin a marker of oxidative stress? Free Radic Res. 2004;38(6):623-8, http://dx.doi.org/10.1080/10 715760410001694044.
25. Turner R, Stamp LK, Kettle AJ. Detection of allantoin in clinical samples using hydrophilic liquid chromatography with stable isotope dilution negative ion tandem mass spectrometry. J Chromatogr B. 2012;891-892:85-9, http://dx.doi.org/10.1016/j.jchromb.2012.02.009.
26. Hellsten Y, Tullson PC, Richter EA, Bangsbo J. Oxidation of urate in human skeletal muscle during exercise. Free Radic Biol Med. 1997;22(1/2):169-74, http://dx.doi. org/10.1016/S0891-5849(96)00286-9.
27. Kattygnarath D, Mounier N, Madelaine-Chambrin I, Gourmel B, Le Bricon T, Gisselbrecht C, et al. Quantification of urinary allantoin by capillary zone electrophoresis during recombinant urate oxidase (rasburicase) therapy. Clin Biochem. 2006;39:86-90, http://dx.doi.org/10.1016/ j.clinbiochem.2005.09.013.
28. Muratsubaki H, Enomoto K, Soejima A, Satake K. An enzyme cycling method for measurement of allantoin in human serum. Anal Biochem. 2008;378:65-70, http://dx.doi. org/10.1016/j.ab.2008.04.013.
29. Causse E, Ribes D, Longlune N, Kamar N, Durand D, Salvayare R, et al. Aminothiols and allantoin in chronic dialysis patients: Effects of hemodialysis sessions. Clin Nephrol. 2010;73(1):51-7, http://dx.doi.org/10.5414/CNP73051.
30. Kurajoh M, Koyama H, Shoji T, Sumida C, Yamamoto A, Tsutsumi Z, et al. Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients. Int J Clin Pharmacol Ther. 2012;50(4): 265-71, http://dx.doi.org/10.5414/CP201582.
31. Pavitt DV, de Fonseka S, Al-Khalaf N, Cam JM, Reaveley DA. Assay of serum allantoin in humans by gas chromatography-mass spectrometry. Clin Chim Acta. 2002;318(1-2): 63-70, http://dx.doi.org/10.1016/S0009-8981(01)00805-1.
32. Gruber J, Tang SY, Jenner AM, Mudway I, Blomberg A, Behndig A, et al. Allantoin in human plasma, serum and nasal-lining fluids as a biomarker of oxidative stress: Avoiding artifacts and establishing real in vivo concentrations. Antioxidants Redox Signaling. 2009;11(8):1767-76, http://dx.doi.org/10.1089/ars.2008.2364.
33. Il'yasova D, Scarbrough P, Spasojevic I. Urinary biomarkers of oxidative status. Clin Chim Acta. 2012;413(19-20): 1446-53, http://dx.doi.org/10.1016/j.cca.2012.06.012.
34. Crankshaw DJ, Rangachari PK. Isoprostanes: More than just mere markers. Mol Cell Biochem. 2003;253:125-30, http://dx.doi.org/10.1023/A:1026052123843.
35. Milne G, Yin H, Jasn D. Human biochemistry of the isoprostane pathway. J Biol Chem. 2008;283:15533-7, http:// dx.doi.org/10.1074/jbc.R700047200.
36. Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: Physiology, pharmacology and clinical implications. Trends Pharmacol Sci 2002;23(8):360-6, http://dx.doi.org/10.1016/S0165-6147(02)02053-9.
37. Milne GL, Musiek ES, Morrow JD. F2-isoprostanes as markers of oxidative stress in vivo: An overview. Biomarkers. 2005;10:S10-S23, http://dx.doi.org/10.1080/1354750 0500216546.
38. Musiek ES, Brooks JD, Joo M, Brunoldi E, Porta A, Zanoni G, et al. Electrophilic cyclopentanoneneuroprostanes are anti-inflammatory mediators formed from the peroxidation of the ω-3 polyunsaturated fatty docosahexaenoic acid. J Biol Chem. 2008;183(29):19927-35, http://dx.doi. org/10.1074/jbc.M803625200.
39. Song WL, Paschos G, Fries S, Reilly M, Yu Y, Rokach J, et al. Novel eicosapentaenoic acid-derived F3-isoprostanes as bio-markers of lipid peroxidation. J Biol Chem. 2009;284 (35):23636-43, http://dx.doi.org/10.1074/jbc.M109.024075.
40. Roberts LJ, Morrow JD. Measurement of F2-isoproastanes as index of oxidative stress in vitro. Free Radic Biol Med. 2000;28:505-13, http://dx.doi.org/10.1016/S0891-58 49(99)00264-6.
41. Pratico D, Lawson JA, Rokach J, FitzGerald GA. The isoprostanes in biology and medicine. Trends Endocrinol Metab. 2001;12(6):243-47, http://dx.doi.org/10.1016/S1043-2760(01)00411-8.
42. Morrow JD, Frei B, Longmire AW, Gaziano M, Lynch SM, Shyr Y, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. N Engl J Med. 1995;332:1198-203, http://dx.doi.org/10.1056/NE JM199505043321804.
43. Gopaul NK, Anggard EE, Mallet AI, Betteridge DJ, Wolff SP, Nouroo-Zadeh J. Plasma 8-epi-PGF2α levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett. 1995;368:225-9, http://dx.doi. org/10.1016/0014-5793(95)00649-T.
44. Keaney JF Jr, Larson Jr MG, Vasan RS, Wilson PWF, Lipinska I, Corey D, et al. Obesity and systemic oxidative stress: Clinical correlates of oxidative stress in the Framingham study. Arterioscler Thromb Vac Biol. 2003;23:434-9, http://dx.doi.org/10.1161/01.ATV.0000058402.34138.11.
45. Reilly MP, Pratico D, Delanty N, DiMinno G, Tremoli E, Rader D, et al. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation. 1998;98: 2822-8, http://dx.doi.org/10.1161/01.CIR.98.25.2822.
46. Obata T, Tomaru K, Nagakura T, Izumi Y, Kawamoto T. Smoking and oxidant stress: Assay of isoprostane in human urine by gas chromatography-mass spectrometry. J Chromatogr B. 2000;746:11-5, http://dx.doi.org/10.1016/ S0378-4347(00)00182-1.
47. Dav I G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, et al. Platelet activation in obese women. Role of inflammation and oxidant stress. JAMA. 2008;288(16):2008-14, http://dx.doi.org/10.1001/ jama.288.16.2008.
48. DavI G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, et al. In vivo formation of 8-iso-prostaglandin F2α and platelet activation in diabetes mellitus: Effect of improved metabolic control and vitamin E supplementation. Circulation. 1999;99:224-29, http://dx.doi. org/10.1161/01.CIR.99.2.224.
49. DavI G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: Role of interleukin-6 and disease duration. Circulation. 2003;107:3199-203, http://dx.doi.org/10.1161/01.CIR. 0000074205.17807.D0.
50. Markesbery WR, Carney JM. Oxidative alterations in Alzheimer's disease. Brain Pathol. 1999;9:133-46, http:// dx.doi.org/10.1111/j.1750-3639.1999.tb00215.x.
51. Pratico D, Iuliano L, Amerio G, Tang LX, Rokach J, Sabatino G, et al. Down's syndrome is associated with increased 8, 12-iso-iPF2α-VI levels: Evidence for enhanced lipid peroxidation in vivo. Ann Neurol. 2000;48:795-89, http://dx.doi.org/10.1002/1531-8249(200011)48:5<795:: AID-ANA15>3.0.CO;2-#.
52. Pratico D, Clark CM, Lee VMY, Trojanowski JQ, Rokach J, FitzGerald GA. Increased 8, 12-iso-iPF2α-VI in Alzheimer's disease: Correlation of noninvasive index of lipid peroxidation with disease severity. Ann Neurol. 2000;48:809-12, http://dx.doi.org/10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9.
53. Balanza SC, Aragones AM, Mir JCC, RamIrez JB, Ivanez R, Soriano AN, et al. Leukotriene B4 and 8-isoprostane in exhaled breath condensate of children with episodic and persistent asthma. J Invest Clin Immunol. 2010;20(3):237-43.
54. Kharitonov SA, Barnes PJ. Exhales markers of pulmonary disease. Am J Respir Crit Care Med. 2001;63:1693-722, http://dx.doi.org/10.1164/ajrccm.163.7.2009041.
55. Baraldi E, Ghiro L, Piovan V, Carro S, Ciabattoni G, Barnes PJ, et al. Increased exhaled 8-isoprostane in childchood asthma. Chest. 2003;124:25-31.
56. Zanconato S, Carro S, Corradi M, Alinovi R, Pasquale MF, Baraldi E. Leukotriene and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma. J Allergy Clin Immunol. 2004;113:257-63, http:// dx.doi.org/10.1016/j.jaci.2003.10.046.
57. Morow JD, Zackert WE, Yang JP, Kurhts EH, Callewaert D, Dworski R, et al. Quantification of the major urinary metabolite of 15-F2t-Isoprostane (8-iso-PGF2α) by a stable isotope dilution mass spectrometric assay. Anal Biochem. 1999;269:326-31, http://dx.doi.org/10. 1006/abio.1999.4008.
58. Morrow JD, Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res. 1997;36(1):1-21, http://dx.doi.org/10.1016/S0163-7827 (97)00001-5.
59. Dorjgochoo T, Gao YT, Chow WH, Shu X, Yang G, Cai Q et al. Major metabolite of F2-isoprostane in urine may be a more sensitive biomarker of oxidative stress than isoprostane itself. Am J Clin Nutr. 2012;96:405-14, http:// dx.doi.org/10.3945/ajcn.112.034918.